Search

Your search keyword '"Saunders, Kevin O."' showing total 459 results

Search Constraints

Start Over You searched for: Author "Saunders, Kevin O." Remove constraint Author: "Saunders, Kevin O."
459 results on '"Saunders, Kevin O."'

Search Results

101. A broadly neutralizing antibody protects against SARS-CoV, pre-emergent bat CoVs, and SARS-CoV-2 variants in mice

102. Chimeric spike mRNA vaccines protect against Sarbecoviruschallenge in mice

103. Broad neutralization of H1 and H3 viruses by adjuvanted influenza HA stem vaccines in nonhuman primates

104. SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys

106. Systematic Assessment of Antiviral Potency, Breadth, and Synergy of Triple Broadly Neutralizing Antibody Combinations against Simian-Human Immunodeficiency Viruses

107. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth

108. Rapid selection of HIV envelopes that bind to neutralizing antibody B cell lineage members with functional improbable mutations

109. The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates

110. SARS-CoV-2 Variant B.1.1.7 is Susceptible to Neutralizing Antibodies Elicited by Ancestral Spike Vaccines

111. Lipid nanoparticle encapsulated nucleoside-modified mRNA vaccines elicit polyfunctional HIV-1 antibodies comparable to proteins in nonhuman primates

112. Mouse and Human Antibodies that Bind HLA-E-Leader Peptide Complexes and Enhance NK Cell Cytotoxicity

113. RAB11FIP5-Deficient Mice Exhibit Cytokine-Related Transcriptomic Signatures

114. Antigenicity and Immunogenicity of HIV-1 Envelope Trimers Complexed to a Small-Molecule Viral Entry Inhibitor

115. Recapitulation of HIV-1 Env-Antibody Coevolution in Macaques Leading to Neutralization Breadth

116. Exploiting Pre-Existing CD4+ T Cell Help from Bacille Calmette–Guérin Vaccination to Improve Antiviral Antibody Responses

117. Fab-dimerized glycan-reactive antibodies neutralize HIV and are prevalent in humans and rhesus macaques

118. Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants

120. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

122. Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency

123. HIV vaccine delayed boosting increases Env variable region 2–specific antibody effector functions

124. Cooperation between somatic mutation and germline-encoded residues enables antibody recognition of HIV-1 envelope glycans

125. Correction: Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

126. Disruption of the HIV-1 Envelope allosteric network blocks CD4-induced rearrangements

127. Neutralization-guided design of HIV-1 envelope trimers with high affinity for the unmutated common ancestor of CH235 lineage CD4bs broadly neutralizing antibodies

128. Star nanoparticles delivering HIV-1 peptide minimal immunogens elicit near-native envelope antibody responses in nonhuman primates

130. Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity

131. Consistent elicitation of cross-clade HIV-neutralizing responses achieved in guinea pigs after fusion peptide priming by repetitive envelope trimer boosting

132. Correction: HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

133. Vaccine Induction of Heterologous Tier 2 HIV-1 Neutralizing Antibodies in Animal Models

134. Author Correction: A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite

135. HIV-1 envelope glycan modifications that permit neutralization by germline-reverted VRC01-class broadly neutralizing antibodies

136. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape

137. Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses

138. Immunogenicity of NYVAC Prime-Protein Boost Human Immunodeficiency Virus Type 1 Envelope Vaccination and Simian-Human Immunodeficiency Virus Challenge of Nonhuman Primates

140. Initiation of HIV neutralizing B cell lineages with sequential envelope immunizations

141. HIV DNA-Adenovirus Multiclade Envelope Vaccine Induces gp41 Antibody Immunodominance in Rhesus Macaques

143. Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial

144. Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates

145. Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses

146. Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.

147. Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal Simian-Human Immunodeficiency Virus Infection

148. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost

149. Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

150. Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection

Catalog

Books, media, physical & digital resources